Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC)

被引：2
|
作者：
Waterhouse, D. M.
Morgan, S. K.
Spigel, D. R.
Shankar, S.
Dharan, B.
Foose, D. E.
Bhatt, K.
机构：
[1] Oncol Hematol Care Inc, Cincinnati, OH USA
[2] Florida Canc Specialists, Naples, FL USA
[3] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[4] GlaxoSmithKline, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7055
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
    Trafalis, Dimitrios T.
    Alifieris, Constantinos
    Stathopoulos, George P.
    Sitaras, Nikolaos
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 713 - 722
  • [42] Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
    Dimitrios T. Trafalis
    Constantinos Alifieris
    George P. Stathopoulos
    Nikolaos Sitaras
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 713 - 722
  • [43] Topotecan (Hycamtin(TM)) in small cell lung cancer (SCLC) after failure of first line therapy: Multicentre phase II study
    vonPawel, J
    Depierre, A
    Hans, K
    Moro, D
    Clark, P
    Gatzemeier, U
    Paillot, N
    Scheithauer, W
    Carmichael, J
    Santoro, A
    Ross, G
    Marangolo, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1038 - 1038
  • [44] A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
    Yun, Tak
    Kim, Heung Tae
    Han, Ji-Youn
    Yoon, Sung Jin
    Kim, Hyae Young
    Nam, Byung-Ho
    Lee, Jin Soo
    CANCER RESEARCH AND TREATMENT, 2016, 48 (02): : 465 - 472
  • [45] Late phase II trials of topotecan (T) for relapsed small cell lung cancer (SCLC)
    Nishiwaki, Y
    Negoro, S
    Watanabe, K
    Fukuoka, M
    Niitani, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S253 - S253
  • [46] A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC).
    Nogami, N.
    Kiura, K.
    Takigawa, N.
    Harita, S.
    Chikamori, K.
    Shibayama, T.
    Tabata, M.
    Hotta, K.
    Shinkai, T.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non-Small-Cell Lung Cancer
    Powell, Steven F.
    Beitinjaneh, Amer
    Tessema, Mathewos
    Bliss, Robin L.
    Kratzke, Robert A.
    Leach, Joseph
    Dudek, Arkadiusz Z.
    CLINICAL LUNG CANCER, 2013, 14 (05) : 495 - 501
  • [48] Effect of Topotecan as Second-Line Chemotherapy for Small Cell Lung Cancer Patients with Interstitial Lung Disease
    Suzuki, H.
    Hirashima, T.
    Kobayashi, M.
    Sasada, S.
    Okamoto, N.
    Uehara, N.
    Matsuura, Y.
    Tamiya, M.
    Morishita, N.
    Higashiguchi, M.
    Tsumori, T.
    Kawase, I.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (06) : 367 - 370
  • [49] Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo plus Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)
    Owonikoko, Taofeek
    Nackaerts, Kristiaan
    Csoszi, Tibor
    Ostoros, Gyula
    Baik, Christina
    Ullmann, Claudio Dansky
    Zagadailov, Erin
    Sheldon-Waniga, Emily
    Huebner, Dirk
    Leonard, E. Jane
    Spigel, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S261 - S262
  • [50] Gemcitabine as second-line treatment for advanced non-small-cell lung cancer:: A phase II trial
    Crinò, L
    Mosconi, AM
    Scagliotti, G
    Selvaggi, G
    Novello, S
    Rinaldi, M
    Della Giulia, M
    Gridelli, C
    Rossi, A
    Calandri, C
    De Marinis, F
    Noseda, M
    Tonato, M
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2081 - 2085
12345